Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.
J Comp Eff Res
; 11(3): 193-202, 2022 02.
Article
en En
| MEDLINE
| ID: mdl-34879742
ABSTRACT
Aim:
To assess the cost-effectiveness of brentuximab vedotin (BV) versus physician's choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials &methods:
A partitioned-survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts.Results:
Over the modeled lifetime, BV dominated physician's choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses.Conclusion:
BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Linfoma Cutáneo de Células T
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
Idioma:
En
Revista:
J Comp Eff Res
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido